Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice.

Atherosclerosis - 1 Dec 2013

Burgmaier Mathias, Liberman Ana, Möllmann Julia, Kahles Florian, Reith Sebastian, Lebherz Corinna, Marx Nikolaus, Lehrke Michael

Abstract excerpt

BACKGROUND: [corrected] Glucagon-like peptide-1 (GLP-1) based therapies are new treatment options for patients with type 2 diabetes. Recent reports suggest vasoprotective actions of GLP-1. Similar beneficial effects might be reached by GLP-1(9-37) and the c-terminal GLP-1 split product (28-37) although both peptides do not activate the GLP-1 receptor. We therefore investigated the actions of GLP-1(7-37),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis
Share to Blood Glucose

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Collagen

Share to Diet, High-Fat

Share to Glucagon-Like Peptide 1

Share to Matrix Metalloproteinase 9

Share to Plaque, Atherosclerotic

Share to Transgenes

Source

Identifiers

PMID: 24267262
DOI: 10.1016/j.atherosclerosis.2013.08.033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice.PMID 24267262Read ↗

The Cardiovascular Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-level Outcomes to Micro-level MechanismsSemantic proximity Read ↗

A novel non-genetic murine model of hyperglycemia and hyperlipidemia-associated aggravated atherosclerosisSemantic proximity Read ↗

Syndecan-1 as a predictor of vulnerable atherosclerotic plaquesSemantic proximity Read ↗

Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress.Semantic proximity Read ↗

SUR1-E1506K mutation impairs glucose tolerance and promotes vulnerable atherosclerotic plaque phenotype in hypercholesterolemic mice.Semantic proximity Read ↗

Small rodent models of atherosclerosis.Semantic proximity Read ↗

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic diseaseSemantic proximity Read ↗

Pharmacological inhibition of protein tyrosine phosphatase 1B protects against atherosclerotic plaque formation in the LDLR-/- mouse model of atherosclerosis.Semantic proximity Read ↗

Mouse models of atherosclerosis and their suitability for the study of myocardial infarction.Semantic proximity Read ↗

Effects of Low Carbohydrate High Protein (LCHP) diet on atherosclerotic plaque phenotype in ApoE/LDLR-/- mice: FT-IR and Raman imaging.Semantic proximity Read ↗

INSULIN-LIKE GROWTH FACTOR I REDUCES CORONARY ATHEROSCLEROSIS IN PIGS WITH FAMILIAL HYPERCHOLESTEROLEMIASemantic proximity Read ↗

Protein deglycase DJ-1 deficiency induces phenotypic switching in vascular smooth muscle cells and exacerbates atherosclerotic plaque instability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.